SHH and hepatocellular carcinoma: Recent report shows that nuclear factor (erythroid-derived 2)-like 2 (NRF2) binds to the promoter of Shh to upregulate Shh mRNA and protein levels, which leads to activation of the Shh pathway and resistance to sorafenib in hepatocellular carcinoma 39.